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Conclusions: DREAMS shows excellent safety and efficacy data up to 2 years in cohort
1 of the BIOSOLVE-I trial. Multi-modality imaging documented the absorption process
and the uncaging aspect of this device already at 6 months.
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Background: The DESolveTM Myolimus-Eluting Bioresorbable Coronary Scaffold
(Elixir Medical Corporation, Sunnyvale, CA) is a novel bioresorbable vascular scaffold
device that combines a PLLA-based scaffold coated with a potent antiproliferative
sirolimus analog agent Myolimus (3 mcg per mm of scaffold length).
Methods: A total of 15 patients with single de novo coronary artery lesions 14mm in
vessels 2.5-3.75 mm in diameter were enrolled in this prospective, multi-center,
single-arm, first-in-man study, and underwent serial angiographic studies at baseline/
index and 6 months follow-up. Primary endpoint was angiographic in-scaffold late lumen
loss, as determined by quantitative coronary angiography (QCA) analysis performed by
an independent angiographci core laboratory.
Results: Overall, 14 patients/lesions were available for paired analysis. The Right
coronary artery was the most prevalent lesion location (43%) and lesion class according
to the ACC/AHA classification demonstrated type A in 36%, type B1 in 29% and type B2
in (36%). Baseline QCA showed mean lesion length, reference diameter (RD), minimum
lumen diameter (MLD) and % diameter stenosis (DS) of 8.952.64mm, 2.650.32mm,
0.810.29mm and 70.010.5%, respectively. During procedure, predilatation was
performed in 93%, postdilatation was performed in 29%, and final TIMI flow was
achieved in 100%. Final and 6-month follow-up QCA analyses are shown in the Table.
Overall, there was only 1 case of in-segment binary restenosis, which involved the
proximal edge outside the scaffold.
Variable In-Scaffold (N14)
Final
- RD, mm 2.770.25
- MLD, mm 2.600.19
- % DS 8.17.9
- Acute gain, mm 1.790.39
Follow-up at 6 months
- RD, mm
- MLD, mm 2.410.28
- % DS 12.611.4
- Late lumen loss, mm 0.190.19
Conclusions: The DESolve device demonstrated excellent performance in non-complex
coronary lesions including high acute gain and optimal expansion at postprocedure as
demonstrated by the low final %DS. At 6-month follow-up, there was relatively low
in-scaffold late lumen loss (0.19mm), suggesting efficacy of this new technology on
inhibiting neointimal hyperplasia.
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Background: Side branch occlusion (SBO) contributes to the periprocedural myocardial
infarction (MI), which has been associated with unfavorable late clinical outcomes.
However, the incidence and acute clinical outcomes of SBO after bioresorbable vascular
scaffold (BVS) implantation has been unexplored.
Methods: Amongst consecutive 469 patients who were enrolled in the ABSORB-
EXTEND single-arm trial from January 2010 to January 2012, a total of 1127 side
branches in 435 patients were evaluated. Although major side branches  2 mm in
diameter was excluded per protocol, any visible side branches originating within
to-be-scaffolded segment or its 5 mm-proximal and -distal margins were included in the
angiographic assessment. SBO was defined as a reduction in thrombolysis in myocardial
infarction (TIMI) flow to grade 0 or 1.
Results: Pre-procedure reference vessel diameter (RVD) and percent diameter stenosis
were 2.62 mm and 58.6 % in the main vessel, and 1.18 mm and 20.0 % in the side branch,
respectively. Post-procedure SBO was observed in 67 out of 1127 side branches (5.9 %),
while it was 9 out of 537 side branches with a RVD of  1.0 mm (1.7 %). Amongst 67
occluded side branches, 60 (89.6 %) were originated within the obstruction segment in the
main vessel, which was automatically delineated by quantitative coronary angiography.
Periprocedural Non-Q-wave MI (NQMI) according to the protocol definition was
adjudicated in 5 patients (mean ratio of peak CK and CKMB to upper limit of normal
were 2.82 and 4.61, respectively) amongst 61 patients with the angiographic evidence of
SBO post-procedure (8.2 %).
Clinical events
SBO
(N61)
Non-SBO
(N374)
Relative Risk
(95% CI) p value
In-hospital
events, % (n)
Cardiac death 0.0 (0/61) 0.0 (0/374) N/A N/A
Myocardial
infarction
8.2 (5/61) 0.5 (2/374) 15.3 (3.0, 77.3) 0.001
Q-wave 0.0 (0/61) 0.0 (0/374) N/A N/A
Non-Q-wave 8.2 (5/61) 0.5 (2/374) 15.3 (3.0, 77.3) 0.001
Ischemia driven
target lesion
revascularization
0.0 (0/61) 0.0 (0/374) N/A N/A
Major adverse
cardiac events
8.2 (5/61) 0.5 (2/374) 15.3 (3.0, 77.3) 0.001
30-days events
(%)
Cardiac death 0.0 (0/61) 0.0 (0/357) N/A N/A
Myocardial
infarction
8.2 (5/61) 1.4 (5/357) 5.9 (1.8, 19.6) 0.008
Q-wave 0.0 (0/61) 0.8 (3/357) 0 1
Non-Q-wave 8.2 (5/61) 0.6 (2/357) 14.6 (2.9, 73.7) 0.001
Ischemia driven
target lesion
revascularization
0.0 (0/61) 0.0 (0/357) N/A N/A
Major adverse
cardiac events
8.2 (5/61) 1.4 (5/357) 5.9 (1.8, 19.6) 0.008
SBO, side branch occlusion; N/A, not available. Analysis was performed by
Fisher’s exact test.
In-hospital is defined as hospitalization  7 days post-procedure.
Conclusions: Although 5.9 % of small side branches occluded after BVS implantation,
the incidence of periprocedural MI was quite limited.
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Background: The impact of left main (LM) revascularization with the unrestricted use
of drug-eluting stents (DES) on long-term clinical outcomes is still a matter of debate.
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